Therapeutic HPV vaccine (PVX7) for advanced cervical cancer
Therapeutic HPV vaccines (PVX7) for Advanced Cervical Cancer
['FUNDING_OTHER'] · JOHNS HOPKINS UNIVERSITY · NIH-11191611
This project tests a new HPV vaccine combination to help prevent recurrence in women who have finished treatment for advanced cervical cancer.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | JOHNS HOPKINS UNIVERSITY (nih funded) |
| Locations | 1 site (BALTIMORE, UNITED STATES) |
| Trial ID | NIH-11191611 on ClinicalTrials.gov |
What this research studies
You would be offered a two-part vaccine that first uses a DNA shot (pBI-11) and then a viral booster (TA-HPV) to teach the immune system to target HPV16 and HPV18 cancer proteins linked to heat shock protein 70. The team will enroll women who completed standard treatment and have no visible cancer but may have tiny amounts of disease left. Doctors will give the vaccines, monitor side effects, measure immune responses, and check blood for cell-free HPV DNA as a marker of hidden cancer. The study aims to show the vaccine is safe and whether blood HPV DNA can indicate persistent HPV-related cancer.
Who could benefit from this research
Good fit: Women who finished standard-of-care therapy for cervical cancer, especially those with HPV16/18-related disease who currently show no clinical tumor but may harbor minimal residual disease, are ideal candidates.
Not a fit: People whose cancers are caused by HPV types other than 16 or 18, or who have active, measurable metastatic disease, are less likely to benefit from this vaccine approach.
Why it matters
Potential benefit: If successful, this approach could help the immune system clear leftover HPV-related cancer cells and lower the chance of recurrence.
How similar studies have performed: Prior related HPV vaccine combinations have been shown to be safe and to stimulate HPV-specific T cell responses, though preventing recurrence remains an emerging goal.
Where this research is happening
BALTIMORE, UNITED STATES
- JOHNS HOPKINS UNIVERSITY — BALTIMORE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: WU, TZYY-CHOOU — JOHNS HOPKINS UNIVERSITY
- Study coordinator: WU, TZYY-CHOOU
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.